A validated in-house assay for HIV drug resistance mutation surveillance from dried blood spot specimens

被引:1
|
作者
Neufeld, Bronwyn [1 ]
Munyuza, Chantal [1 ]
Reimer, Alexandria [1 ]
Capina, Rupert [1 ]
Lee, Emma R. [1 ]
Becker, Marissa [2 ,3 ]
Sandstrom, Paul [1 ]
Ji, Hezhao [1 ,2 ]
Cholette, Francois
机构
[1] Natl Sexually Transmitted & Blood Borne Infect Lab, Natl Microbiol Lab, Publ Hlth Agcy Canada, JC Wilt Infect Dis Res Ctr, 745 Logan Ave, Winnipeg, MB R3E 3L5, Canada
[2] Univ Manitoba, Max Rady Coll Med, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada
基金
美国国家卫生研究院;
关键词
HIV; Drug resistance; Dried blood spots; Surveillance; GENOTYPING ASSAY; VIRAL LOAD; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; FIELD-EVALUATION; SUBTYPE-B; GENOMES; AFRICA; PLASMA; PCR;
D O I
10.1016/j.jviromet.2024.114939
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95 % CI: 3200-10,700) copies/mL for the protease gene and 3600 (95 % CI: 2200-10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8 % [95 % CI: 92.2-99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7 % [36.1-57.5] and 60.0 % [49.1-70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping
    Chen, J. H. K.
    Wong, K. H.
    Chan, K.
    Lam, H. Y.
    Lee, S. S.
    Li, P.
    Lee, M. P.
    Tsang, D. N.
    Zheng, B. J.
    Yuen, K. Y.
    Yam, W. C.
    JOURNAL OF CLINICAL VIROLOGY, 2007, 39 (02) : 125 - 131
  • [32] Dried blood spots for HIV-1 Drug Resistance and Viral Load Testing: A Review of Current Knowledge and WHO Efforts for Global HIV Drug Resistance Surveillance
    Bertagnolio, Silvia
    Parkin, Neil T.
    Jordan, Michael
    Brooke, James
    Garcia-Lerma, J. Gerardo
    AIDS REVIEWS, 2010, 12 (04) : 195 - 208
  • [33] Development, Validation and Clinical Evaluation of a Low Cost In-House HIV-1 Drug Resistance Genotyping Assay for Indian Patients
    Acharya, Arpan
    Vaniawala, Salil
    Shah, Parth
    Misra, Rabindra Nath
    Wani, Minal
    Mukhopadhyaya, Pratap N.
    PLOS ONE, 2014, 9 (08):
  • [34] Diagnosis and quantification of pediatric HIV-1 infection by an ultrasensitive HIV-1 p24 assay adapted to dried blood spot specimens
    Knuchel, Marlyse C.
    Jullu, Boniphace Salustian
    Shah, Cyril
    Tomasik, Zuzana
    Stoeckle, Marcel P.
    Speck, Roberto F.
    Nadal, David
    Mshinda, Hassan
    Boeni, Juerg
    Tanner, Marcel
    Schuepbach, Joerg
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 75 (05): : 93 - 93
  • [35] A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1
    Lindström, A
    Albert, J
    JOURNAL OF VIROLOGICAL METHODS, 2003, 107 (01) : 45 - 51
  • [36] Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate-a validated assay for the clinic
    Hooff, Gero P.
    Meesters, Roland J. W.
    van Kampen, Jeroen J. A.
    van Huizen, Nick A.
    Koch, Birgit
    Al Hadithy, Asmar F. Y.
    van Gelder, Teun
    Osterhaus, Albert D. M. E.
    Gruters, Rob A.
    Luider, Theo M.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2011, 400 (10) : 3473 - 3479
  • [37] Clinical Evaluation of an In-House Human Immunodeficiency Virus (HIV) Genotyping Assay for the Detection of Drug Resistance Mutations in HIV-1 Infected Patients in Singapore
    Thew, Kuan Kiat
    Ng, Kah Ying
    Khong, Wei Xin
    Kaur, Palvinder
    Yap, Joe Kwan
    Chua, Arlene
    Tan, Mei Ting
    Koh, Yin Ling
    Thoon, Koh Cheng
    Leo, Yee Sin
    Ng, Oon Tek
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2012, 41 (12) : 553 - 558
  • [38] Implementation of a point mutation assay for HIV drug resistance testing in Kenya
    Duarte, Horacio A.
    Beck, Ingrid A.
    Levine, Molly
    Kiptinness, Catherine
    Kingoo, James M.
    Chohan, Bhavna
    Sakr, Samah R.
    Chung, Michael H.
    Frenkel, Lisa M.
    AIDS, 2018, 32 (16) : 2301 - 2308
  • [39] Protein bead array for the detection of HIV-1 antibodies from fresh plasma and dried-blood-spot specimens
    Faucher, S
    Martel, A
    Sherring, A
    Ding, T
    Malloch, L
    Kim, JE
    Bergeron, M
    Sandstrom, P
    Mandy, FF
    CLINICAL CHEMISTRY, 2004, 50 (07) : 1250 - 1253
  • [40] Evaluation of dried blood spots for HIV-1 drug resistance testing
    García-Lerma, J
    McNulty, A
    Jennings, C
    Bennett, D
    Fitzgibbon, J
    Morack, R
    Ussery, M
    Folks, TM
    Kalish, ML
    Heneine, W
    ANTIVIRAL THERAPY, 2005, 10 (04) : S49 - S49